Icon

TOBI (nda050753)- (300MG/5ML)

TOBRAMYCIN MYLAN SPECIALITY LP
300MG/5ML
Yes No
2014-Oct-19 Expired
None None
None No
TOBI is an aminoglycoside antibacterial indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa.
9 0 9
Total Other Developers 13
Drugs with Suitability No
300MG/5ML ** ** - - 7
NDA Sales Available Total Generic Sales Available
Yes 8
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** **** ****** *** ****** ********** ******* *********** ***** **** *****, ********** **** ********** ******, ******* *****, *******, ******** *** ***, ****** ******* (***) ***
****** ***** *** ******** *********** *********** * ********** ******, ********, ***** ******** (**) *****, ****** ****** (***) ***
****** ****** ****** ****** ***************, *** *********** * *** ******* *** **** *, **********, *** ****** (**) *****-****, ****** ****** (***) ***
****** ****** ****** ******** ****** *********, *** *********** **** ********** *****, **********, ******** (**) *****, ****** ****** (***) ***
****** ** ****** **** ** ******** ****************** **** *********** **********., ********-******, - *****, ******* (***) ***
****** *** ***** *** ************** ******** ******* *********** ****** **. ** *** ** - ******* :- ***** **** - *****, ***** **********, ******* ******, ***** (***) ***
****** ***** **** *** ******** ****************** **** *********** **********., ********-******, - *****, ******* (***) ***
****** ******* ****** ******* ****** ******* *********** ****-***, ******* *****, ****** **** ****, ***. ****** *******, ****** *****, *******, ******** ******* ******, ***** (***) ***
****** ***** **** ***** **** ******* *********** ***-***, ** *****, ****** **** ****, *****, *********** ********** ****, *********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.